Lyra Therapeutics

LYRA · NASDAQ

$0.19−$0.16 (−45.71%)TodayMarket closed · Oct 20, 3:54 PM ET

Prev close $0.35

About LYRA

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 27 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).

Employees: 27
Headquarters: Watertown, Massachusetts
Listed: May 1, 2020
Sector: Health Care
Industry: Pharmaceuticals
Website: lyratherapeutics.com

Leadership

Lyra Therapeutics executives
Name	Title	Age
Richard Nieman	—	61
James Tobin	—	80
C. Ann Merrifield	—	73
W. Bradford Smith	—	68
Nancy Snyderman	—	73

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Lyra Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
LianBio ADR LIAN	Supplier and customer	US	—

Similar companies

Companies in the same industry as Lyra Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.